Company announces positive data from phase 3 trial (RHAPSODY) of rilonacept in recurrent pericarditis

RCT (n=61) found median time to recurrence for patients on rilonacept, a recombinant fusion protein that blocks IL-1α and IL-1β signalling, in withdrawal period, could not be estimated due to low number of recurrences vs.8.6 weeks for placebo recipients (HR0.04, p<0.0001).


Biospace Inc.